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Higher cardiorespiratory fitness predicts long-term 
survival in patients with heart failure and preserved 
ejection fraction: the Henry Ford Exercise Testing (FIT) 
Project
Olusola A. Orimoloye1, Swetha Kambhampati2, Albert J. Hicks III3, Mahmoud Al Rifai1,  
Michael G. Silverman4, Seamus Whelton1, Waqas Qureshi5, Jonathan K. Ehrman6,  
Steven J. Keteyian6, Clinton A. Brawner6, Zeina Dardari1, Mouaz H. Al-Mallah7, Michael J. Blaha1
A b s t r a c t
Introduction: Higher cardiorespiratory fitness (CRF) is associated with im-
proved exercise capacity and quality of life in heart failure with preserved 
ejection fraction (HFpEF), but there are no large studies evaluating the associ-
ation of HFpEF, CRF, and long-term survival. We therefore aimed to determine 
the association between CRF and all-cause mortality, in patients with HFpEF.
Material and methods: In the Henry Ford Exercise Testing (FIT) Project, 167 
patients had baseline HFpEF, defined as a clinical diagnosis of heart failure 
with ejection fraction ≥ 50% on echocardiogram. The CRF was estimated 
from the peak workload (in METs) from a clinician-referred treadmill stress 
test and categorized as poor (1–4 METs), intermediate (5–6 METs), and mod-
erate-high (≥ 7 METs). Additional analyses assessing the effect of HFpEF 
and CRF on mortality were also conducted, matching HFpEF patients to non- 
HFpEF patients using propensity scores. 
Results: Mean age was 64 ±13 years, with 55% women, and 46% Black. Over 
a median follow-up of 9.7 (5.2–18.9) years, there were 103 deaths. In fully 
adjusted models, moderate-high CRF was associated with 63% lower mor-
tality risk (HR = 0.37, 95% CI: 0.18–0.73) compared to the poor-CRF group. 
In the propensity-matched cohort, HFpEF was associated with a HR of 2.3 
(95% CI: 1.7–3.2) for mortality compared to non-HFpEF patients, which was 
attenuated to 1.8 (95% CI: 1.3–2.5) after adjusting for CRF.
Conclusions: Moderate-high CRF in patients with HFpEF is associated with im-
proved survival, and differences in CRF partly explain the intrinsic risk of HFpEF. 
Randomized trials of interventions aimed at improving CRF in HFpEF are needed.
Key words: cardiovascular disease, risk prediction, risk assessment, heart 
failure.
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Introduction
Heart failure with preserved ejection fraction 
(HFpEF) accounts for nearly half of heart failure 
hospitalizations and more than half of the heart 
failure mortality in the US [1]. A combination of its 
prevalence, outcomes, and future projections has 
led to a  description of HFpEF as the single larg-
est unmet need in cardiovascular medicine [1]. 
Despite this high prevalence of HFpEF in the heart 
failure subpopulation, there are few effective ther-
apies to improve mortality outcomes in these pa-
tients and few methods for risk stratification [2, 3].
The assessment of cardiorespiratory fitness 
(CRF), a health-related component of physical fit-
ness defined as the ability of the circulatory and 
respiratory systems to supply oxygen to skeletal 
muscles during sustained physical activity [4], has 
been proposed as a tool for risk stratification in this 
heart failure subpopulation. There have also been 
suggestions that improving this measure may lead 
to better outcomes in patients with HFpEF.
Numerous studies have shown graded inverse 
associations of morbidity and mortality with CRF 
across multiple populations [5], including healthy 
[6], diabetic [7], overweight [8], and hypertensive 
individuals [9], as well as in patients with heart 
disease [10], and following myocardial infarction 
[11]. Similarly, in heart failure with reduced ejec-
tion fraction (HFrEF), low CRF has been shown to 
be associated with increased mortality in patients 
with ischemic cardiomyopathy, non-ischemic car-
diomyopathy, and patients being evaluated for 
heart transplantation [12–14].
High levels of CRF have been shown to improve 
or prevent many of the comorbidities commonly 
seen with HFpEF, including hypertension, obesity, 
anemia, diabetes, renal dysfunction, and impaired 
left ventricular compliance [1]. Although these 
comorbidities have been shown to be associated 
with HFpEF or the ventricular-vascular dysfunc-
tion seen in patients with HFpEF, they do not fully 
account for the poor outcomes seen in the HFpEF 
population [15]. When HFpEF patients were com-
pared to matched patients enrolled in clinical tri-
als, the HFpEF population still demonstrated sig-
nificantly higher mortality [15].
Currently, there are limited data examining 
the association of CRF and survival in HFpEF pa-
tients [16]. Trials of exercise training in HFpEF 
populations have only reported short-term fol-
low-up data, and are thus not adequately pow-
ered to evaluate mortality [17–19]. This lack of 
large HFpEF cohorts, multiple negative treatment 
trials, and lack of long-term follow-up have con-
tributed to the paucity of interventions in HFpEF 
and methods for HFpEF risk stratification. Under-
standing the association of CRF and mortality in 
patients with HFpEF is an important step toward 
developing interventions aimed at prolonging life 
in patients with HFpEF. Programs such as cardiac 
rehabilitation may be better supported and reim-
bursed with data suggesting that such interven-
tions may improve survival in these patients. 
Given the foregoing, we aimed to study the as-
sociation between CRF and long-term mortality in 
patients with HFpEF isolated from the Henry Ford 
Exercise Testing Project (the FIT Project) cohort. 
We hypothesized that higher CRF would be inde-
pendently associated with lower risk of death and 
that this association would be similar for both HF-
pEF and non-HFpEF individuals. 
Material and methods
Study design
We examined data from the FIT Project, an in-
vestigator-initiated retrospective cohort study of 
69,885 patients who underwent a  physician-re-
ferred exercise stress testing at Henry Ford Health 
System affiliated subsidiaries in metropolitan 
Detroit, MI between 1991 and 2009. The FIT Proj-
ect rationale and design have been previously 
described [20]. Briefly, the FIT Project was assem-
bled using directly measured exercise data, and 
retrospectively collected medical and medication 
history. Verification and supplementation of miss-
ing data was performed using electronic medi-
cal records (EMR), administrative databases, and 
pharmacy claims files. The FIT Project determined 
total mortality via linkage with the Social Security 
Administration Death Master File, and select non-
fatal outcomes through medical claims files [20].
Study cohort and identification of HFpEF
The study sample consists of individuals within 
the FIT project who had a prior clinical diagnosis 
of congestive heart failure and available tread-
mill data, who demonstrated ejection fraction of 
≥ 50% within 1 year of the clinical treadmill test.
The clinical diagnosis of heart failure was made 
either during the intake report taken by the nurse 
at the start of the test or by an EMR-based diag-
nosis requiring at least three occurrences of heart 
failure ICD-9 code 428.XX in the patient’s chart. 
In all cases, the history of heart failure was con-
firmed by linkage with administrative claims files 
confirming a history of a billing diagnosis of heart 
failure.
Specifically, we first considered 1,596 patients 
who had documented heart failure within the FIT 
project. Of this number, 575 had a clinical tread-
mill test within 1 year of an echocardiogram (the 
median time from treadmill test to echocardio-
gram in our HFpEF cohort was 53 days). Of this 
number, a  total of 165 patients had an echocar-
diogram with a documented ejection fraction (EF) 
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≥ 50%, and these comprise the study population. 
HFpEF was thus defined in this study as an es-
tablished clinical diagnosis of heart failure with an 
associated ejection fraction (EF) ≥ 50% on echo-
cardiogram.
Mortality assessment
The primary outcome was all-cause mortality 
with a  median follow-up time of 9.7 (5.2–13.9) 
years. Mortality ascertainment was conducted us-
ing social security number, first name, last name, 
and date of birth to search the Social Security 
Death Index Death Master File until April 2013. 
A complete search was done in over 99.5% of all 
the patients in the FIT database [20].
Treadmill stress testing and estimation  
of cardiorespiratory fitness
All patients underwent routine clinical treadmill 
stress testing using the standard protocol [21]. In-
dication for stress test referral was provided by 
the referring physician, and subsequently catego-
rized into common indications (chest pain, short-
ness of breath, “rule out” ischemia, or other). The 
treadmill test was symptom-limited and was ter-
minated if the patient had exercise-limiting chest 
pain, shortness of breath, or other limiting symp-
toms as assessed by the supervising clinician. In 
accordance with American Heart Association and 
American College of Cardiology (AHA/ACC) guide-
lines [22], testing could be terminated early at the 
discretion of the clinician for significant arrhyth-
mias, abnormal hemodynamic responses, diag-
nostic ST-segment changes, or if the participant 
was unwilling or unable to continue. 
Resting heart rates and blood pressures were 
taken in the seated position prior to stress testing, 
and percent of maximal heart rate achieved was 
based on the age-predicted maximal heart rate 
formula: 220 – age. CRF was expressed in meta-
bolic equivalents of task (METs), which was calcu-
lated by the Quinton treadmill controller based on 
achieved speed and elevation [23]. Full MET credit 
for a stage was provided once a patient completed 
at least 1.5 min of the 3-minute stage. The follow-
ing CRF categories were used: poor (1–4 METs), 
intermediate (5–6 METs), and moderate-high 
(≥ 7 METs). The poor CRF category was defined 
based on previous systolic heart failure fitness 
data which showed worse mortality for patients 
who achieved 4 or less METs [13]. 
Measurement of covariates
Demographic information, indication for stress 
test, risk factor burden, past medical history, and 
active medication use were obtained by a nurse 
and/or exercise physiologist immediately prior to 
the stress test. A smoking history was defined as 
self-reported history of smoking. Other risk fac-
tors, medical history, and medication data were 
then augmented by a retrospective search of the 
EMR. A  database-verified diagnosis was consid-
ered present when the appropriate Internation-
al Classification of Diseases, 9th Revision (ICD-9) 
code was present on more than 3 separate en-
counters within the Henry Ford health system. Hy-
pertension was defined as a prior diagnosis of hy-
pertension, use of anti-hypertensive medications, 
or a database-verified diagnosis of hypertension. 
The blood pressure at the time of the test was not 
used to diagnose hypertension. Diabetes mellitus 
was defined as a prior diagnosis of diabetes, use 
of hypoglycemic medications including insulin, 
or EMR problem list-based diagnosis of diabetes. 
A  history of coronary artery disease (CAD) was 
defined as prior myocardial infarction, coronary 
angioplasty, coronary artery bypass surgery, or 
prior documented obstructive CAD on a prior an-
giogram. Weight was measured at the time of ini-
tial stress testing. Estimated glomerular filtration 
rates (GFR) were calculated using the Levey Mod-
ification of Diet in Renal Disease formula, where 
GFR = 175 × standardized Screatinine
–1.154 × age–0.203 × 
1.212 (if Black) × 0.742 (if female) [24]. 
Statistical analysis
Baseline characteristics of the study cohort were 
summarized for each of the 3 CRF groups. Categor-
ical variables were reported as percent frequencies 
and compared using the c2 test, while continuous 
variables were presented as means ± standard de-
viation and compared using ANOVA. 
Crude incidence rates of all-cause mortali-
ty were calculated and reported per 1000 per-
son-years. Kaplan-Meier survival curves for each 
CRF group were constructed and compared via log 
rank testing. The proportional hazards assump-
tion was tested and confirmed using comple-
mentary log-log plots. Multivariable Cox regres-
sion models were used to assess the association 
between METs and all-cause mortality using the 
lowest CRF category as the reference (METs ≤ 4). 
Model 1 was adjusted for demographics of age, 
sex, and race. Model 2 was further adjusted for 
modifiable risk factors including hypertension, di-
abetes mellitus, smoking status, and weight. Mod-
el 3 was additionally adjusted for medication use 
including β-blockers, angiotensin-converting en-
zyme inhibitors (ACEI), angiotensin receptor block-
ers, and medications for chronic lung disease (i.e. 
inhalers). Model 4 was further adjusted for history 
of CAD to account for potential ischemia-related 
limitations in CRF. We also modeled METs continu-
ously and calculated the risk of all-cause mortality 
per 1 unit increase of METs. 
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Additionally, we sought to evaluate the risk of 
mortality associated with a HFpEF diagnosis when 
compared to non-HFpEF patients with similar tra-
ditional risk factors and similar CRF. To do this, 
we created a propensity score-matched cohort of 
non-HFpEF patients drawn from the larger FIT co-
hort, excluding patients with heart failure with re-
duced ejection fraction. Propensity score matching 
was performed using nearest-neighbor matching 
in a 1 : 3 fashion accounting for 5 variables (the 
limit of our statistical power): age, sex, race, hyper-
tension and diabetes mellitus. In subsequent sur-
vival analyses using this matched cohort, models 
were adjusted for smoking status, β-blockers, ACEI, 
lung disease medications, known CAD, and statins, 
as these variables remained residually significantly 
different between the 2 cohorts. 
Finally, to study whether there was a differen-
tial benefit of CRF in the HFpEF versus non-HF-
pEF cohort, we fit separate survival models for 
CRF and mortality in patients with and without 
HFpEF to formally test for effect measure mod-
ification. 
All reported p-values were two-sided and 
a p-value < 0.05 was considered statistically sig-
nificant. All analyses were performed using Stata 
version 13.1 (StataCorp, College Station, Texas).
Results
Baseline characteristics are summarized in Ta-
ble I. The mean age of the overall HFpEF cohort 
was 64 ±13 years, 55% were female, 46% were 
Black and 52% were white. There were 90 (54%) 
HFpEF patients in the poor CRF group, 33 (20%) 
in the intermediate group, and 44 (26%) in the 
moderate-high group. Patients in the lower CRF 
categories were older, had a lower eGFR, and were 
more likely to be female and diabetic (p < 0.05). 
92.9% of the entire HFpEF cohort had hyper-
Table I. Baseline characteristics of the study population stratified by METs categories
Parameter Total popu-
lation
(N = 167)
Poor CRF
METs 1–4 
(N = 90)
Intermediate 
CRF
METs 5–6 
(N = 33)
Moderate- 
high CRF
METs ≥ 7
(N = 44)
P-value
Demographic characteristics:
Age [years] 63.9 ±12.5 67 ±10.9 59.1 ±15.9 61.0 ±11.1 0.002
Gender, n, %: 0.01
Female 91, 54.5 18, 54.6 18, 54.6 28, 63.6
Male 76, 45.5 33, 36.7 15, 45.5 16, 36.4
Race, n, %: 0.57
White 86, 51.5 45, 50.0 14, 42.4 27, 61.4
Black 77, 46.1 43, 47.8 18, 54.6 16, 36.4
Others 4, 2.4 2, 2.2 1, 3.0 1, 2.3
Clinical characteristics:
Hypertension, n, % 155, 92.8 86, 95.6 31, 93.9 38, 86.4 0.15
Diabetes, n, % 70, 41.9 47, 52.2 11, 33.3 12, 27.3 0.01
History of CAD, n, % 94, 56.3 51, 56.7 18, 54.6 25, 56.8 0.98
Smoking history, n, % 55, 32.9 29, 32.2 9, 27.3 17, 38.6 0.56
Estimated glomerular filtration rate 66.9 ±30.3 60.6 ±33.6 75.8 ±22.9 74.3 ±24.0 0.03
Weight [lbs] 179.6 ±44.3 176.1 ±45.3 176.2 ±40.8 189.8 ±44.1 0.16
Medication use, n, %:
β-Blocker use 67, 40.1 31, 34.4 18, 54.6 18, 40.9 0.13
ACEi use 79, 47.3 45, 50.0 17, 51.5 17, 38.6 0.40
ARB use 3, 1.8 1, 1.1 1, 3.0 1, 2.27 0.75
Use of lung disease medications 30, 18.0 18, 20 3, 9.1 9, 20.45 0.045
ACEi – angiotensin-converting enzyme inhibitors, ARB – angiotensin receptor blockers, CAD – coronary artery disease. Data represent 
proportions or means ± standard deviations.
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tension, while usage of medications such as 
β-blockers and ACE Inhibitors was 40.1% and 
47.3% respectively.
There were 103 (62%) deaths in the entire 
HFpEF cohort during the follow-up period. After 
5 years, 36% of patients in the poor CRF catego-
ry, 18% of those in the intermediate CRF group, 
and 4.6% in the moderate to high CRF group were 
deceased (Table II). Throughout the follow-up, pa-
tients in higher fitness groups maintained a sur-
vival advantage over those in lower fitness groups 
(Figure 1).
The crude incidence rate of death decreased 
from 84 to 37 deaths per 1000 person-years going 
from poor to moderate-high CRF. In unadjusted 
models, compared to the poor CRF group, moder-
ate-high CRF was associated with 64% lower risk of 
mortality (HR = 0.36, 95% CI: 0.19–0.67) (Figure 2). 
The survival advantage in the moderate-high 
CRF group persisted in the fully adjusted model 
(HR = 0.37, 95% CI: 0.18–0.73). No significant risk 
reduction in mortality was seen when the inter-
mediate CRF group was compared to the poor CRF 
group. There was a 13% reduction in mortality per 
1 unit higher METs (HR = 0.87, 95% CI: 0.78–0.96), 
which remained significant and unchanged after 
full adjustment (HR = 0.86, 95% CI: 0.77–0.97). 
Risk factor and CRF-adjusted effect  
of HFpEF on mortality risk
Baseline characteristics of propensity-matched 
study population are as described in Table III. After 
multivariable adjustments, the long-term mortali-
Table II. Mortality rates of the study population with HFpEF stratified by METs categories
Death Total, n, % 1–4 METs, n, % 5–6 METs, n, % ≥ 7 METs, n, % P-value
At 1 year 10, 6.0 7, 7.8 3, 9.1 0, 0 0.14
At 2 years 17, 10.2 13, 14.4 4, 12.1 0, 0 0.03
At 3 years 26, 15.6 20, 22.22 5, 15.2 1, 2.3 0.01
At 4 years 31, 18.6 25, 27.8 5, 15.2 1, 2.3 0.001
At 5 years 40, 24.0 32, 35.6 6, 18.2 2, 4.6 < 0.001
At 7 years 59, 35.3 41, 45.6 13, 39.4 5, 11.4 < 0.001
At 10 years 78, 46.7 50, 55.6 16, 48.5 12, 27.3 0.008
 0 2 4 6 8 10
Time [years]
Number at risk:
METs 1–4
 90 77 65 56 43 40
METs 5–6
 33 29 28 24 19 16
METs ≥ 7
 44 44 43 40 37 27
 METs1–4          METs 5–6          METs ≥ 7
Figure 1. Kaplan-Meier curves of all-cause mortali-
ty by METs group for the HFpEF study population
1.0
0.8
0.6
0.4
Figure 2. Multivariable-adjusted hazard ratios (95% 
confidence interval) for the association of CRF and 
all-cause mortality in the HFpEF population
Multivariable Hazard ratio
Cox (95% CI)
Regression
Unadjusted:
Reference 1.00 (1.00–1.00)
5–6 METs 0.79 (0.45–1.38)
≥ 7 METs 0.36 (0.19–0.67)
Per MET 0.87 (0.78–0.96)
Model 1 (age, sex and race) 
Reference 1.00 (1.00–1.00)
5–6 METs 0.81 (0.46–1.44)
≥ 7 METs 0.33 (0.17–0.64)
Per MET 0.86 (0.77–0.95)
Model 2 (model 1 + risk factors)
Reference 1.00 (1.00–1.00)
5–6 METs 0.95 (0.53–1.70)
≥ 7 METs 0.38 (0.19–0.76)
Per MET 0.88 (0.78–0.98)
Model 3 
(model 2 + risk medications)
Reference 1.00 (1.00–1.00)
5–6 METs 0.92 (0.50–1.70)
≥ 7 METs 0.38 (0.19–0.75)
Per MET 0.87 (0.78–0.97)
Model 4 
(model 3 + history of CAD)
Reference 1.00 (1.00–1.00)
5–6 METs 0.92 (0.51–1.69)
≥ 7 METs 0.37 (0.18–0.73)
Per MET 0.86 (0.77–0.97)
 0.1 0.5  1.0 1.5 2.0
 Favors higher METs Favors lower METs
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ty risk of the HFpEF cohort was significantly high-
er than the propensity-matched non-HFpEF cohort 
(HR = 2.3, 95% CI: 1.7–3.2). After further adjust-
ment for CRF (modeled as continuous METs), the 
mortality risk associated with HFpEF diminished 
Table IV. Association between HFpEF and incident all-cause mortality with and without adjustment for cardiore-
spiratory fitness
HFpEF Unadjusted
HR (95% CI)
Adjusted*
HR (95% CI)
Without METs 2.6 (2.0–3.5) 2.3 (1.7–3.2)
With METs (continuous) 1.9 (1.4–2.6) 1.8 (1.3–2.5)
With METs (categorical) 2.0 (1.5–2.7) 1.9 (1.4–2.6)
*Models adjusted for smoking status, use of β-blockers, use of ACE inhibitors, use of lung disease medications, known CAD and statin use, 
as these variables remained residually statistically significant following propensity matching.
Table III. Baseline characteristics of propensity-matched study population
Parameter Case (N = 167) Control (N = 501) P-value
Mean METs 4.7 ±2.5 6.3 ±2.8 < 0.001
METs categories, n, %:
1–4 90, 53.9 131, 26.2 < 0.001
5–6 33, 19.8 111, 22.2
≥ 7 44, 26.4 259, 51.7
Matched on:
Age [years] 63.9 ±12.5 63.9 ±11.3 0.99
Gender, n, %: 0.89
Females 91, 54.5 270, 53.9
Males 76, 45.5 231, 46.11
Race, n, %: 0.96
White 86, 51.5 264, 52.7
Black 77, 46.1 226, 45.1
Other 4, 2.4 11, 2.2
Diabetes, n, % 70, 41.9 224, 44.7 0.53
Hypertension, n, % 155, 92.9 457, 91.22 0.52
Not matched on:
Smoking, n, % 55, 32.9 197, 39.3 0.14
β-Blockers, n, % 67, 40.1 242, 48.3 0.07
ACEI, n, % 79, 47.3 147, 29.3 < 0.001
ARB, n, % 3, 1.80 7, 1.40 0.71
Use of lung disease medications, n, % 30, 18.0 40, 8.0 < 0.001
Known CAD, n, % 94, 56.3 223, 44.5
GFR 66.9 ±30.3 77.1 ±24.7 < 0.001
Weight 179.6 ±44.3 181.6 ±39.4 0.60
Statin, n, % 42, 25.2 157, 31.3 0.13
Death percentage, n, % 78, 46.7 104, 20.8 < 0.001
ACEI – angiotensin-converting enzyme inhibitors, ARB – angiotensin receptor blockers, CAD – coronary artery disease, GFR – glomerular 
filtration. Data represent proportions or means ± standard deviations.
but was still significant (HR = 1.8, 95% CI: 1.3–
2.5), suggesting that CRF partly accounted for the 
association between HFpEF and mortality. Similar 
results were obtained when we adjusted for METs 
as a categorical variable (Table IV).
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Figure 3. A – Multivariable-adjusted hazard ratios (95% confidence interval) for the association between CRF and 
incident all-cause mortality by HFpEF status. B – Interaction analysis: multivariable-adjusted hazard ratios (95% 
confidence interval) for the association between CRF and all-cause mortality
Case control
Analysis:
Multivariable Hazard ratio
Cox regression (95% CI)
No HFpEF (controls)
Reference 1.00 (1.00–1.00)
5–6 METs 0.58 (0.35–0.94)
≥ 7 METs 0.35 (0.21–0.57)
Per MET 0.79 (0.72–0.87)
HFpEF (cases)
Reference 1.00 (1.00–1.00)
5–6 METs 0.89 (0.50–1.61)
≥ 7 METs 0.375 (0.19–0.72)
Per MET 0.87 (0.78–0.97)
Case control
Analysis:
Multivariable Hazard ratio
Cox regression (95% CI)
No HFpEF (controls)
Reference 1.00 (1.00–1.00)
5–6 METs 0.68 (0.47–0.99)
≥ 7 METs 0.35 (0.23–0.52)
HFpEF (cases)
1–4 METs 2.00 (1.40–2.70)
5–6 METs 1.35 (0.67–2.70)
≥ 7 METs 0.69 (0.33–1.40)
A B
 0.1 0.5 1 2
 Favors higher METs Favors lower METs
 0.1 0.5 1 2
 Favors higher METs Favors lower METs
Assessment of modification of CRF effect 
by HFpEF status
The analysis shown in Figure 3 A  presents 
hazard ratios of mortality with increasing METs 
for both the HFpEF and non-HFpEF cohorts, with 
the METs 1–4 category as the reference in each 
respective group. Higher CRF from poor to mod-
erate-high was significantly associated with 
lower mortality risk in both the HFpEF and non- 
HFpEF cohorts, without evidence of interaction 
(p = 0.32), suggesting that the association be-
tween CRF and mortality appears similar regard-
less of HFpEF status.
Figure 3 B presents hazard ratios of mortal-
ity comparing HFpEF and non-HFpEF using the 
non-HFpEF cohort with poor CRF (METs 1–4) as 
the reference category. This analysis demonstrat-
ed that while moderate-high CRF had a  statisti-
cally lower mortality risk compared to poor CRF 
in non-HFpEF patients, HFpEF patients regardless 
of CRF had similar mortality to the poor CRF non- 
HFpEF group. 
Discussion
The results of our study demonstrate that in HF-
pEF patients, higher CRF levels were inversely as-
sociated with all-cause mortality compared to poor 
CRF. We confirm, through a  propensity matched 
analysis, that the diagnosis of HFpEF is inde-
pendently associated with mortality, and extend ex-
isting literature by showing that this risk is partially 
explained by diminished CRF levels. Furthermore, 
we found no significant interaction between CRF 
and HFpEF, suggesting that the improved survival 
associated with higher CRF appears to be similar 
for both HFpEF and non-HFpEF cohorts matched for 
age, gender, and cardiovascular risk factors. 
The results of this study are of marked clinical 
importance as they indicate that data from the 
straightforward and widely available treadmill 
exercise stress test can provide important prog-
nostic information in patients with HFpEF, and 
suggest that improving CRF may potentially yield 
a mortality benefit in this population.
Our study has several strengths. First, the FIT 
dataset is the largest epidemiologic database of 
objectively assessed clinical exercise data to date. 
Our study population was racially diverse, with 
nearly 50% Black subjects, and was also sex-bal-
anced, with nearly 50% women. In addition, the 
duration of follow-up extends to 15 years for all-
cause mortality, with more than 50% of patients 
followed for at least 10 years. 
In the present study, we showed that HFpEF pa-
tients in the FIT Project had a significantly worse 
mortality per CRF category compared to a propen-
sity-matched cohort, even after multivariable ad-
justment for other residual differences. We showed 
however, that this association between HFpEF and 
mortality is at least partly explained by decreased 
CRF. This is consistent with other cardiovascular 
studies that have shown higher mortality rates 
for HFpEF compared to non-HFpEF patients and 
suggests that HFpEF is associated with mortali-
ty via both CRF-dependent and CRF-independent 
mechanisms. Studies on HFpEF hemodynamic re-
sponses to exercise have described a number of 
maladaptations that may contribute to the worse 
outcomes in this population including chrono-
tropic incompetence [25], poor augmentation of 
cardiac output [26], reduced peripheral arterial 
blood flow [27], and impaired skeletal muscle me-
tabolism [28]. Indeed, HFpEF patients are known 
to have poor exercise tolerance demonstrated by 
a  lower peak oxygen uptake, a  blunted cardiac 
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output increase during exercise, and a robust rise 
in left ventricular and pulmonary filling pressures 
compared to healthy non-HFpEF populations [29].
Even though our data suggest improved long-
term survival in HFpEF patients who achieved an 
estimated MET level of 7 or more (moderate-high 
CRF) on treadmill exercise testing, it is unknown 
whether targeting exercise training in HFpEF pa-
tients to achieve a CRF level of at least 7 METs will 
improve mortality. Our cohort did show a signif-
icant 18% lower risk for long-term mortality for 
every MET achieved, so it is possible that improve-
ments in METs through exercise training might 
show similar long-term mortality benefit in the 
HFpEF population. Further studies are required to 
examine whether CRF-oriented exercise training 
in HFpEF patients will improve survival. Neverthe-
less, this study demonstrates that the low-cost 
intervention of a treadmill exercise stress test can 
provide significant risk stratification for HFpEF pa-
tients regardless of multiple comorbidities.
Our results extend the evidence from the find-
ings of prior studies, which have demonstrated 
that exercise training and improved CRF in pa-
tients with HFpEF are associated with clinical im-
provement. Some studies have also shown that 
exercise training improves exercise capacity and 
quality of life, and this benefit is associated with 
atrial reverse remodeling and improved left ven-
tricular diastolic function through favorable cardi-
ac remodeling [30]. Similarly, a large meta-analy-
sis evaluating the efficacy of exercise training in 
patients with HFpEF found that exercise training 
was associated with an improvement in CRF and 
quality of life [18].
Overall, in the absence of effective pharmaco-
logic treatments available for patients with HFpEF, 
regular exercise training has shown strong ob-
jective evidence in improving quality of life and 
functional capacity for patients with HFpEF [31, 
32]. This study therefore sheds light on improved 
mortality over long-term follow-up with CRF in pa-
tients with HFpEF, which has not been sufficiently 
demonstrated in the existing literature.
Our study has a number of limitations that war-
rant acknowledgment. First, the FIT Project reports 
the experience of a single health system with its 
unique practice patterns and modes of operation. 
Although the study population is diverse, it may 
not be representative of the general US popula-
tion. Patients who completed a different protocol 
for stress testing were not included in the FIT Proj-
ect, potentially excluding patients who are less 
fit, unable to exercise on a treadmill or those who 
were referred for pharmacological stress testing. 
This may have excluded the sickest heart failure 
patients, given that the protocol used can be chal-
lenging for heart failure patients. 
Some subjects were allowed to use handrails, 
so our exercise data may not be fully representa-
tive of true exercise capacity. While this may atten-
uate our effect estimates, this is more representa-
tive of what would be obtained in a clinical setting, 
as it is reflective of clinical safety practices. 
In conclusion, moderate-to-high CRF (≥ 7 METs) 
on baseline treadmill testing is associated with 
a  survival benefit in HFpEF patients. The ben-
efit observed in HFpEF patients is similar to the 
well-described benefit of CRF in non-HFpEF pa-
tients. Future studies should investigate wheth-
er targeted exercise training to achieve at least 
moderate-high CRF would reduce mortality in this 
high-risk population.
The results of our study demonstrate the im-
portance of measuring CRF in HFpEF patients, 
with a  moderate-high CRF (METs ≥ 7) inversely 
associated with all-cause mortality after multi-
variable adjustment. We confirm that a  HFpEF 
diagnosis is independently associated with mor-
tality, and extend existing literature by showing 
that this risk is partially explained by diminished 
CRF levels. Furthermore, there appears to be no 
evidence of interaction between CRF and HFpEF, 
suggesting that improved survival associated with 
higher CRF appears to be similar for both HFpEF 
and non-HFpEF populations matched for age, gen-
der, and cardiovascular risk factors.
Our data alert clinicians to the importance of 
CRF in determining long-term survival in patients 
with HFpEF. This study also suggests that strate-
gies to increase CRF, such as cardiac rehabilitation, 
may potentially be beneficial in the management 
of patients with HFpEF.
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